Beam Therapeutics Inc.
BEAM
$26.75
$0.240.91%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -98.46% | -72.19% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -98.46% | -72.19% | |||
| Cost of Revenue | -9.02% | 5.29% | |||
| Gross Profit | -29.98% | -590.67% | |||
| SG&A Expenses | -7.21% | 6.66% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -8.57% | 5.62% | |||
| Operating Income | -18.04% | -514.59% | |||
| Income Before Tax | -30.07% | -138.61% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -30.07% | -138.61% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -30.07% | -138.61% | |||
| EBIT | -18.04% | -514.59% | |||
| EBITDA | -19.22% | -762.78% | |||
| EPS Basic | -28.74% | -138.46% | |||
| Normalized Basic EPS | -28.64% | -138.05% | |||
| EPS Diluted | -28.74% | -139.23% | |||
| Normalized Diluted EPS | -28.64% | -138.80% | |||
| Average Basic Shares Outstanding | 1.03% | 0.37% | |||
| Average Diluted Shares Outstanding | 1.03% | -1.59% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||